Form 8-K - Current report:
SEC Accession No. 0001628280-22-004080
Filing Date
2022-02-28
Accepted
2022-02-28 06:08:11
Documents
14
Period of Report
2022-02-28
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K auph-20220228.htm   iXBRL 8-K 37682
2 EX-99.1 exhibit991_q42021pressrele.htm EX-99.1 119751
6 aurinalogo.jpg GRAPHIC 11010
  Complete submission text file 0001628280-22-004080.txt   319031

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20220228.xsd EX-101.SCH 1942
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20220228_lab.xml EX-101.LAB 23970
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20220228_pre.xml EX-101.PRE 12668
8 EXTRACTED XBRL INSTANCE DOCUMENT auph-20220228_htm.xml XML 10834
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 22683765
SIC: 2834 Pharmaceutical Preparations